IDEXX offers Catalyst SDMA test to point-of-care customersJanuary 8, 2018IDEXX Laboratories Inc. announced that its Catalyst SDMA test will be commercially available to all North American customers on Jan. 16, enabling IDEXX's point-of-care customers to add SDMA as an essential element of the routine chemistry panel. The Catalyst SDMA test can be added to any chemistry panel on IDEXX's Catalyst One and Catalyst Dx chemistry analyzers as part of the patient sample run, with the full chemistry panel results, including SDMA, available within minutes. The company expects to bring the Catalyst SDMA test to customers beyond the U.S. and Canada over the course of the next several months. Additionally, to further explore SDMA's potential applications to human health, the company has signed a collaboration agreement with Yale University. As part of this partnership, the IDEXX SDMA test was validated for accuracy in measuring SDMA in human blood samples, and the results were presented at the 2017 annual meeting of the American Society of Nephrology last November by Yale and IDEXX researchers. Future research with Yale will focus on the clinical utility of SDMA in human patients using the validated IDEXX SDMA Test. IDEXX first launched the IDEXX SDMA test at its reference laboratories in 2015, and has run …
SPONSORED CONTENTSwitch to Triple Protection in One Monthly DoseSee the difference of triple protection with the one monthly chew. + Learn More
